WCM
ALNY icon

WealthTrak Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

WealthTrak Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-6
Closed -$1.96K – 116
2025
Q2 		$1.96K Buy
6
+4
+200% +$1.11K ﹤0.01% 442
2025
Q1 		$541 Buy
2
+1
+100% +$257 ﹤0.01% 640
2024
Q4 		$236 Buy
+1
New +$263 ﹤0.01% 769

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

WealthTrak Capital Management's ALNY Position: Q3 2025 in Review

WealthTrak Capital Management sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2025, closing a stake of 6 shares — an estimated $1.96K sold.

WealthTrak Capital Management first reported a position in ALNY in Q4 2024 and held it in 3 quarters. The position peaked at $1.96K in Q2 2025. 823 funds tracked by Wall St. Rank hold ALNY as of Q3 2025.

  • WealthTrak Capital Management reported no remaining Alnylam Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • WealthTrak Capital Management sold 6 Alnylam Pharmaceuticals shares in Q3 2025, an estimated $1.96K.
  • WealthTrak Capital Management first reported a position in Alnylam Pharmaceuticals in Q4 2024 and held it in 3 quarters.
  • WealthTrak Capital Management's Alnylam Pharmaceuticals position peaked at $1.96K in Q2 2025.
  • 823 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2025.

Based on WealthTrak Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.